Drugs / TH-CART-027
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07384390 | Jan 2026 → Aug 2028 expected | glioma | Shanghai Tongji Hospital, Tongji University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06951425 | Jun 2025 → Nov 2028 expected | cancer | Shanghai Tongji Hospital, Tongji University School of Medicine | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TH-CART-027 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06951425 ↗ |
| Modality | Cell therapy | “TH027 CAR-T Cells (TH-CART-027)” NCT06951425 ↗ |
| Route | Intravenous | “Intraperitoneal Infusion for Ovarian Cancer and Peritoneal Metastatic Tumors; Intravenous Infusion for Other Types of Solid Tumors” NCT06951425 ↗ |